关于头孢哌酮与丁胺卡那霉素治疗急性肾盂肾炎的比较分析
|
摘要
目的比较头孢哌酮与丁胺卡那霉素治疗急性肾盂肾炎的临床疗效。方法选取2016年5月～2018年4月我院收治的96例急性肾盂肾炎患者,按照随机数字表法将其分为对照组(48例)和研究组(48例),对照组予以丁胺卡那霉素注射液静脉滴注,研究组予以头孢哌酮注射液静脉滴注,并比较不同组患者临床疗效、尿培养转阴率以及不良反应发生率。结果研究组患者临床治疗总有效率以及尿培养转阴率均高于对照组,但两组比较差异不显著(P>0.05);研究组患者不良反应发生率显著低于对照组,两组比较差异显著(P<0.05)。结论丁胺卡那霉素和头孢哌酮治疗急性肾盂肾炎疗效相当,但后者不良反应发生率更少。
Objective To compare the clinical efficacy of cefoperazone and amikacin in the treatment of acute pyelonephritis.Methods 96 patients with acute pyelonephritis admitted to our hospital from May 2016 to April 2018 were randomly divided into the control group(48 cases) and the study group(48 cases).The control group received amikacin.Intravenous infusion of natamycin injection,the study group was given intravenous infusion of cefoperazone injection,and the clinical efficacy,urine culture conversion rate and adverse reaction rate of different groups were compared.Results The total effective rate of clinical treatment and the negative rate of urine culture in the study group were higher than those in the control group, but the difference between the two groups was not significant(P>0.05).The incidence of adverse reactions in the study group was significantly lower than that in the control group.Significant(P<0.05).Conclusion Amikacin and cefoperazone are equally effective in the treatment of acute pyelonephritis, but the latter has a lower incidence of adverse reactions.
Objective To compare the clinical efficacy of cefoperazone and amikacin in the treatment of acute pyelonephritis.Methods 96 patients with acute pyelonephritis admitted to our hospital from May 2016 to April 2018 were randomly divided into the control group(48 cases) and the study group(48 cases).The control group received amikacin.Intravenous infusion of natamycin injection,the study group was given intravenous infusion of cefoperazone injection,and the clinical efficacy,urine culture conversion rate and adverse reaction rate of different groups were compared.Results The total effective rate of clinical treatment and the negative rate of urine culture in the study group were higher than those in the control group, but the difference between the two groups was not significant(P>0.05).The incidence of adverse reactions in the study group was significantly lower than that in the control group.Significant(P<0.05).Conclusion Amikacin and cefoperazone are equally effective in the treatment of acute pyelonephritis, but the latter has a lower incidence of adverse reactions.
引文
[1]刘义强.肾舒颗粒联合头孢哌酮钠舒巴坦钠治疗慢性肾盂肾炎的临床研究[J].现代药物与临床.2016,31(11):1764-1767.
[2]王松波.头孢哌酮舒巴坦治疗急慢性肾孟肾炎的疗效观察[J].中国医学工程.2012,20(12):48.
[3]郝海英,郑朝霞,巩楠.头孢哌酮舒巴坦钠联合三金片治疗肾盂肾炎的临床观察[J].中国医学创新.2010,7(25):80-81.
[4]李娟.头孢哌酮联合舒巴坦治疗肾盂肾炎的临床疗效和生存质量研究[J].药物评价研究,2016,39(4):652-655.
[5]李娟.头孢哌酮联合舒巴坦治疗肾盂肾炎的临床疗效和生存质量研究[J].药物评价研究,2016,39(4):652-655.
[6]周冠兴.头孢哌酮联合舒巴坦治疗肾盂肾炎55例临床分析[J].现代诊断与治疗,2016,27(8):1433-1435.
[7]付海尔,李瑜.头孢哌酮联合舒巴坦治疗肾盂肾炎30例[J].中国实用医刊,2015,42(19):42-43.
[8]司玉梅,李涛,陈新河,等.霉酚酸酯联合激素治疗重症紫癜性肾炎[J].湖北医药学院学报,2010,29(5):447-448.
[2]王松波.头孢哌酮舒巴坦治疗急慢性肾孟肾炎的疗效观察[J].中国医学工程.2012,20(12):48.
[3]郝海英,郑朝霞,巩楠.头孢哌酮舒巴坦钠联合三金片治疗肾盂肾炎的临床观察[J].中国医学创新.2010,7(25):80-81.
[4]李娟.头孢哌酮联合舒巴坦治疗肾盂肾炎的临床疗效和生存质量研究[J].药物评价研究,2016,39(4):652-655.
[5]李娟.头孢哌酮联合舒巴坦治疗肾盂肾炎的临床疗效和生存质量研究[J].药物评价研究,2016,39(4):652-655.
[6]周冠兴.头孢哌酮联合舒巴坦治疗肾盂肾炎55例临床分析[J].现代诊断与治疗,2016,27(8):1433-1435.
[7]付海尔,李瑜.头孢哌酮联合舒巴坦治疗肾盂肾炎30例[J].中国实用医刊,2015,42(19):42-43.
[8]司玉梅,李涛,陈新河,等.霉酚酸酯联合激素治疗重症紫癜性肾炎[J].湖北医药学院学报,2010,29(5):447-448.